[1]李春燕 汪祥勇 刘剑雄.Omecamtiv Mecarbil在射血分数降低性心力衰竭中的临床研究进展[J].心血管病学进展,2023,(3):243.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.012]
　LI ChunyanWANG XiangyongLIU Jianxiong.Clinical Study of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction[J].Advances in Cardiovascular Diseases,2023,(3):243.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.012]
点击复制

Omecamtiv Mecarbil在射血分数降低性心力衰竭中的临床研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年3期
页码:
243
栏目:
综述
出版日期:
2023-03-25

文章信息/Info

Title:
Clinical Study of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction
作者:
李春燕1 汪祥勇 1 刘剑雄 ; 2
(1.遵义医科大学研究生院,贵州 遵义 563003;2.遵义医科大学附属成都市第二人民医院心血管内科,四川 成都 610017)
Author(s):
LI Chunyan1WANG Xiangyong1LIU Jianxiong12
( 1 Zunyi Medical University Graduate School,Zunyi 563003,Guizhou,China; 2 Department of Cardiology,Chengdu Second Peoples Hospital Affiliated with Zunyi Medical University,Chengdu 610017,Sichuan,China)
关键词:
Omecamtiv mecarbil; 肌球蛋白激活剂; 射血分数降低性心力衰竭
Keywords:
Omecamtiv mecarbil; Myosin agonist;  Heart failure with r educed ejection fraction
DOI:
10.16806/j.cnki.issn.1004-3934.2023.03.012
摘要:
心力衰竭是21世纪危害人类健康的一种临床综合征，射血分数降低性心力衰竭（HFrEF）在全球范围内造成较高的致残率和死亡率。omecamtiv mecarbil已被证实可用于改善HFrEF患者的心功能，降低心室容积、心率和血浆利尿钠肽水平，其机制可能与其直接增强心肌肌节功能相关。现阐述omecamtiv mecarbil在HFrEF防治方面的最新研究进展，为心力衰竭的治疗提供新思路。
Abstract:
Heart failure is a clinical syndrome that threatens human health in the 21st century,and heart failure with reduced ejection fraction(HFrEF) cause s a high rate of disability and mortality worldwide. Omecamtiv mecarbil has been shown to improve cardiac function in patients with HFrEF. Omecamtiv mecarbil decreases ventricular volumes,heart rate and plasma natriuretic peptide levels. The mechanism may be related to its direct enhancement of myocardial segmental function. This article describes the latest research progress of omecamtiv mecarbil in the prevention and treatment of HFrEF,providing new ideas for the treatment of heart failure

参考文献/References:


[1] Tanai E,Frantz S. Pathophysiology of heart failure[J]. Compr Physiol,2015,6(1):187-214.

[2] Murphy SP,Ibrahim NE,Januzzi JL Jr. Heart failure with reduced ejection fraction:a review[J]. JAMA,2020,324(5):488-504.

[3] Okwuosa IS,Princewill O,Nwabueze C,et al. The ABCs of managing systolic heart failure:past,present,and future[J]. Cleve Clin J Med,2016,83(10):753-765.

[4] Ponikowski P,Voors AA,Anker SD,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC) Developed with the special contribution of the Heart Failure Association(HFA) of the ESC[J]. Eur Heart J,2016,37(27):2129-2200.

[5] Li H,Duan Y,Chen B,et al. New pharmacological treatments for heart failure with reduced ejection fraction(HFrEF):a Bayesian network meta-analysis[J]. Medicine (Baltimore) ,2020,99(5):e18341.

[6] Teerlink JR,Diaz R,Felker GM,et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure[J]. N Engl J Med ,2021,384(2):105-116.

[7] Psotka MA,Gottlieb SS,Francis GS,et al. Cardiac calcitropes,myotropes,and?mitotropes:JACC review topic of the week[J]. J Am Coll Cardiol,2019,73(18):2345-2353.

[8] Malik FI,Hartman JJ,Elias KA,et al. Cardiac myosin activation:a potential therapeutic approach for systolic heart failure[J]. Science,2011,331(6023):1439-1443.

[9] Psotka MA,Teerlink JR. Direct myosin activation by omecamtiv mecarbil for heart failure with reduced ejection fraction[J]. Handb Exp Pharmacol,2017,243:465-490.

更新日期/Last Update: 2023-04-24